<VariationArchive VariationID="1184503" VariationName="NM_016180.5(SLC45A2):c.533_534dup (p.Gly179fs)" VariationType="Duplication" Accession="VCV001184503" Version="6" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-05-19" DateCreated="2021-07-28" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1174276" VariationID="1184503">
      <GeneList>
        <Gene Symbol="SLC45A2" FullName="solute carrier family 45 member 2" GeneID="51151" HGNC_ID="HGNC:16472" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>5p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="33944623" stop="33984693" display_start="33944623" display_stop="33984693" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="5" Accession="NT_187551.1" start="145945" stop="155829" display_start="145945" display_stop="155829" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="33944720" stop="33984779" display_start="33944720" display_stop="33984779" Strand="-" />
          </Location>
          <OMIM>606202</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_016180.5(SLC45A2):c.533_534dup (p.Gly179fs)</Name>
      <CanonicalSPDI>NC_000005.10:33982263:CT:CTCT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>5p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="33982263" stop="33982264" display_start="33982263" display_stop="33982264" variantLength="2" positionVCF="33982263" referenceAlleleVCF="C" alternateAlleleVCF="CCT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="33982368" stop="33982369" display_start="33982368" display_stop="33982369" variantLength="2" positionVCF="33982368" referenceAlleleVCF="C" alternateAlleleVCF="CCT" />
      </Location>
      <ProteinChange>G179fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000005.10" sequenceAccession="NC_000005" sequenceVersion="10" change="g.33982264_33982265dup" Assembly="GRCh38">
            <Expression>NC_000005.10:g.33982264_33982265dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000005.9" sequenceAccession="NC_000005" sequenceVersion="9" change="g.33982369_33982370dup" Assembly="GRCh37">
            <Expression>NC_000005.9:g.33982369_33982370dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011691.2" sequenceAccession="NG_011691" sequenceVersion="2" change="g.7411_7412dup">
            <Expression>NG_011691.2:g.7411_7412dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001012509.4" sequenceAccession="NM_001012509" sequenceVersion="4" change="c.533_534dup">
            <Expression>NM_001012509.4:c.533_534dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001012527.2" sequenceAccession="NP_001012527" sequenceVersion="2" change="p.Gly179fs">
            <Expression>NP_001012527.2:p.Gly179fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001297417.4" sequenceAccession="NM_001297417" sequenceVersion="4" change="c.533_534dup">
            <Expression>NM_001297417.4:c.533_534dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001284346.2" sequenceAccession="NP_001284346" sequenceVersion="2" change="p.Gly179fs">
            <Expression>NP_001284346.2:p.Gly179fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_016180.5" sequenceAccession="NM_016180" sequenceVersion="5" change="c.533_534dup" MANESelect="true">
            <Expression>NM_016180.5:c.533_534dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_057264.4" sequenceAccession="NP_057264" sequenceVersion="4" change="p.Gly179fs">
            <Expression>NP_057264.4:p.Gly179fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_016180.4" sequenceAccession="NM_016180" sequenceVersion="4" change="c.533_534dupAG">
            <Expression>NM_016180.4:c.533_534dupAG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="757344228" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00001" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00002" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00002" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_016180.5(SLC45A2):c.533_534dup (p.Gly179fs) AND Oculocutaneous albinism type 4" Accession="RCV001542578" Version="2">
        <ClassifiedConditionList TraitSetID="1241">
          <ClassifiedCondition DB="MedGen" ID="C1847836">Oculocutaneous albinism type 4</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_016180.5(SLC45A2):c.533_534dup (p.Gly179fs) AND not provided" Accession="RCV001882612" Version="3">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-05-23" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_016180.5(SLC45A2):c.533_534dup (p.Gly179fs) AND SLC45A2-related disorder" Accession="RCV003394125" Version="4">
        <ClassifiedConditionList TraitSetID="91513">
          <ClassifiedCondition>SLC45A2-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-12-09" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-05-23" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2021-07-28" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">21458243</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26573111</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">34078970</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1241" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="5663" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Oculocutaneous albinism type 4</ElementValue>
                <XRef ID="Oculocutaneous+albinism%2C+type+4/9033" DB="Genetic Alliance" />
                <XRef ID="MONDO:0011683" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Albinism, oculocutaneous, type IV</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">OCA4</ElementValue>
                <XRef Type="MIM" ID="606574" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Oculocutaneous albinism type 4 (OCA4) is characterized by hypopigmentation of the hair and skin plus the characteristic ocular changes found in all other types of albinism, including: nystagmus; reduced iris pigment with iris translucency; reduced retinal pigment with visualization of the choroidal blood vessels on ophthalmoscopic examination; foveal hypoplasia associated with reduction in visual acuity; and misrouting of the optic nerves at the chiasm associated with alternating strabismus, reduced stereoscopic vision, and an altered visual evoked potential (VEP). Individuals with OCA4 are usually recognized within the first year of life because of hypopigmentation of the hair and skin and the ocular features of nystagmus and strabismus. Vision is likely to be stable after early childhood. The amount of cutaneous pigmentation in OCA4 ranges from minimal to near normal. Newborns with OCA4 usually have some pigment in their hair, with color ranging from silvery white to light yellow. Hair color may darken with time, but does not vary significantly from childhood to adulthood.</Attribute>
                <XRef ID="NBK1510" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16722" />
                <XRef ID="16722" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301683</ID>
                <ID Source="BookShelf">NBK1510</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">37053367</ID>
                <ID Source="BookShelf">NBK590568</ID>
              </Citation>
              <XRef ID="79435" DB="Orphanet" />
              <XRef ID="C1847836" DB="MedGen" />
              <XRef ID="MONDO:0011683" DB="MONDO" />
              <XRef Type="MIM" ID="606574" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="91513" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="71587" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">SLC45A2-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">SLC45A2-related disorder</ElementValue>
              </Name>
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="3463249" SubmissionDate="2021-07-15" DateLastUpdated="2021-07-28" DateCreated="2021-07-28">
        <ClinVarSubmissionID localKey="NC_000005.9:g.33982369_33982370dup|OMIM:606574" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001760161" DateUpdated="2021-07-28" DateCreated="2021-07-28" Type="SCV" Version="1" SubmitterName="Genomics England Pilot Project, Genomics England" OrgID="508170" OrganizationCategory="laboratory" OrgAbbreviation="GeL_Pilot" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACGS Guidelines, 2016</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/ylgat5th/acgs_best_practice_guidelines_for_variant_classification_in_rare_disease_2020.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000005.9:g.33982369_33982370dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="606574" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10010620</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7695615" SubmissionDate="2023-10-19" DateLastUpdated="2023-11-20" DateCreated="2023-11-20">
        <ClinVarSubmissionID localKey="12118522|SLC45A2-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004120126" DateUpdated="2023-11-20" DateCreated="2023-11-20" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" OrgAbbreviation="PG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-12-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The SLC45A2 c.533_534dupAG variant is predicted to result in a frameshift and premature protein termination (p.Gly179Argfs*23). This variant was reported in the heterozygous state along with a second plausible causative variant in individuals with oculocutaneous albinism (Kruijt et al. 2021. PubMed ID: 34078970). This variant is reported in 0.0046% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/5-33982368-C-CCT). Frameshift variants in SLC45A2 are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC45A2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_016180.4:c.533_534dupAG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">SLC45A2-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13915440</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4261231" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="14070049|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002245946" DateUpdated="2024-02-28" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21458243</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26573111</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">34078970</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Gly179Argfs*23) in the SLC45A2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC45A2 are known to be pathogenic (PMID: 21458243, 26573111). This variant is present in population databases (rs757344228, gnomAD 0.005%). This premature translational stop signal has been observed in individual(s) with oculocutaneous albinism (PMID: 34078970). ClinVar contains an entry for this variant (Variation ID: 1184503). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC45A2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000005.9:g.33982368_33982369insCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4261231" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3463249" TraitType="Disease" MappingType="XRef" MappingValue="606574" MappingRef="OMIM">
        <MedGen CUI="C1847836" Name="Oculocutaneous albinism type 4" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7695615" TraitType="Disease" MappingType="Name" MappingValue="SLC45A2-related condition" MappingRef="Preferred">
        <MedGen CUI="None" Name="SLC45A2-related disorder" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>